In This Section

Contact
E-mail
moorthyg [at] email.chop.edu
Phone
Location - People View
Room 4012

3501 Civic Center Blvd
Philadelphia, PA 19104
United States

Research Topics
Ganesh Moorthy, PhD
Ganesh Moorthy, PhD
Director, Bioanalytical Core Laboratory, Center for Clinical Pharmacology

Dr. Moorthy’s research focuses on liquid chromatography-tandem mass spectrometry assays for translational research. He is an expert in developing and validating analytical methods and their implementation for pediatric and adult clinical sample analysis.

AddtoAny
Share:

Bio

Dr. Moorthy is a versatile scientist with 20 years of experience in liquid chromatography-tandem mass spectrometry (LC-MS/MS) and its application in basic research, drug discovery, and development. He is also an expert in the application of LC-MS/MS for quantitative bioanalysis and preclinical pharmacokinetic analysis.

Dr. Moorthy has extensive experience with various biological sample extraction procedures, LC-MS/MS analysis, problem solving, data interpretation, and reporting of drug metabolism and pharmacokinetic studies. He has broad experience in design, execution and interpretation of in vitro and in vivo pharmacology studies.

Among his accomplishments to date, Dr. Moorthy:

  • Worked with the team who discovered dabrafenib, a selective inhibitor of Raf kinases with anti-tumor activity against B-Raf driven tumors. Dabrafenib received FDA approval in 2013 for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation. He also contributed to the development of MEK inhibitor trametinib, which received FDA approved in 2013.
  • Worked closely with PIs and researchers as part of the Bioanalytical Core laboratory of the Center for Clinical Pharmacology at CHOP, and contributed to preclinical, translational, and clinical research projects by providing quantitative bioanalysis of drugs, metabolites, and biomarkers.
  • Led the efforts in the development and validation of a sensitive volumetric absorptive microsampling (VAMS) assay for voriconazole and voriconazole N-oxide in human whole blood. His current research is on the development, validation, and implementation of VAMS assays for analysis of cefepime, vancomycin, and cannabinoids.

Dr. Moorthy has extensive experience in mentoring scientists to develop, validate, and implement robust analytical methods. His team evaluates and uses new tools and microsampling technologies to facilitate preclinical, translational, and clinical research. 

Education and Training

BSc, Bharathiyar University (Chemistry), 1998

MSc, Indian Institute of Technology (Chemistry), 1990

PhD, Case Western Reserve University (Chemistry), 1997

Titles and Academic Titles

Director, Bioanalytical Core Laboratory

Research Assistant Professor of Anesthesiology and Critical Care Medicine

Professional Memberships

American Society for Mass Spectrometry, 1999-

American College of Clinical Pharmacology, 2014-

The Institute for Translational Medicine and Therapeutics, 2015-

The American Society for Clinical Pharmacology and Therapeutics, 2016-

Professional Awards

Nominee for Vice-Chancellor's Award for Excellence in Postdoctoral Research, University of California, Los Angeles, 2000

Honor Award for Identification of Novel Metabolic Pathways, Oxygen Society of California, 2001

Silver Recognition Award for Contribution to Oral Pleuromutilin Clinical Candidate Selection, MMPD Center for Excellence in Drug Discovery, GlaxoSmithKline Pharmaceuticals, 2003

Bronze Recognition Award for Completion of IND Documents, Drug Metabolism and Pharmacokinetics, MMPD Center for Excellence in Drug Discovery, GlaxoSmithKline Pharmaceuticals, 2004

Exceptional Science Award for Contributions to Lead Optimization, MMPD Center for Excellence in Drug Discovery, GlaxoSmithKline Pharmaceuticals, 2005

Award for Novel Drug Target Proposals, Center for Excellence in External Drug Discovery, GlaxoSmithKline Pharmaceuticals, 2006

Silver Recognition Award for Exceptional Program Support, Oncology Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, 2007

Silver Recognition Award for Oncology Program Clinical Candidate Selection, Oncology Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, 2007

Silver Recognition Award for Oncology Program Clinical Candidate (Dabrafenib) Selection, Cancer Research Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, 2008

AB SCIEX Academic Partnership Program, 2017

Publication Highlights

Moorthy GS, Vedar C, Zane N, Prodell JL, Zuppa AF. Development and validation of a volumetric absorptive microsampling assay for analysis of voriconazole and voriconazole N-oxide in human whole blood.. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan; 1105:67-75. PubMed PMID: 30572203
Moorthy GS, Vedar C, Moorthy AS, Prodell JL, Zuppa AF. An improved ultra-high-performance liquid chromatography-tandem mass spectrometric method for the quantitation of dexmedetomidine in small volume of pediatric plasma. Biomed Chromatogr. 2019 Jan; 33(6):e4487. PubMed PMID: 30664276
Moorthy GS, Vedar C, DiLiberto MA, Zuppa AF. A patient-centric liquid chromatography-tandem mass spectrometry microsampling assay for analysis of cannabinoids in human whole blood: Application to pediatric pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jan; 1130-1131:121828. PubMed PMID: 31670108
Elia J, Unsal G, Kao C, Ambrosini A, De Jesus-Rosario N, Larson L, Chiavacci R, Wang T, Kurian C, Titchen K, Sykes B, Hwang S, Kumar B, Potts J, Davis J, Malatack J, Slattery E, Moorthy G, Zuppa AF, Weller A, Byrne E, Li Y, Kraft W, Hakonarson H. Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling. Nat Commun. 2018 Jan; 9(1):4. PMID: 29339723